BPG is committed to discovery and dissemination of knowledge
Correspondence
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastroenterol. Sep 7, 2026; 32(33): 118981
Published online Sep 7, 2026. doi: 10.3748/wjg.118981
Letter to the Editor: Integrative mechanistic exploration in gastrointestinal therapeutics: Exemplified by Chaihu-Shugan-San for chronic atrophic gastritis
Yan Pan, Fu-Yong Jiao
Yan Pan, Department of Pediatrics, The First Affiliated Hospital of Yangtze University, Jingzhou 434000, Hubei Province, China
Fu-Yong Jiao, Shaanxi Kawasaki Disease Diagnosis and Treatment Center, Children’s Hospital, Shaanxi Provincial People’s Hospital, Xi’an Jiaotong University, Xi’an 710000, Shaanxi Province, China
Author contributions: Pan Y designed the study and wrote the manuscript; Jiao FY performed the literature review and critically revised the manuscript and is responsible for all communication. All authors read and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Fu-Yong Jiao, MD, PhD, Shaanxi Kawasaki Disease Diagnosis and Treatment Center, Children’s Hospital, Shaanxi Provincial People’s Hospital, Xi’an Jiaotong University, No. 256 Youyi West Road, Beilin District, Xi’an 710000, Shaanxi Province, China. 3105089948@qq.com
Received: January 16, 2026
Revised: February 3, 2026
Accepted: March 4, 2026
Published online: September 7, 2026
Processing time: 206 Days and 7.1 Hours
Core Tip

Core Tip: This paper emphasizes that the research of Song et al is an example of the integrated research of gastroenterology. Through the combination of network pharmacology, experimental validation and microbiome analysis, this study clarified how Chaihu-Shugan-San can improve chronic atrophic gastritis by double inhibiting inflammation and apoptosis driven by nuclear factor kappa B, and regulating intestinal flora. This paper critically evaluates this methodology as a blueprint for future research on complex botanical drugs, and emphasizes the need for subsequent clinical trials, standardization of phytochemistry, and the development of integrated biomarker groups, in order to translate these mechanistic insights into personalized clinical practice for precancerous lesions.

Write to the Help Desk